Biopharma Funds Regain Some Health

At least one fund is in the black, and several others moved closer to breakeven in October.

Stephen Taub November 17, 2022

Illustration by II

A number of biopharma hedge funds enjoyed a healthier October.These were led by the Soleus Capital Master Fund, which moved back into the black after gaining 5 percent for the month. It is now up nearly 3 percent for the year, according to two investors.Meanwhile,

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Market Intelligence

Data & Analysis

Guest Contributors

II Networks

Insights

Research

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.11.04 build:2025-12-05 Login